Delivery Order SPE2DB20D2002-SPE2DB24FL10U
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Ondansetron ODT 4 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,685.40, is a firm-fixed-price delivery order with a completion date of February 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Ondansetron ODT 4 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $6,372.60, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of $999,999,999 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award is to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) for the delivery of Ondansetron ODT 4 mg tablets. The firm-fixed-price delivery order, valued at $2,446.96, has an ultimate completion date of January 26, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,803.50, is for the delivery of ondansetron odt 8 mg tablets and is designated as a firm fixed price delivery order. The contract has an ultimate completion date of May 1, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Ondansetron HCL 4 mg tablets. The award, valued at $71,197.54, is a Firm-Fixed-Price Delivery Order that runs through September 19, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,455.02 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCl tablets. The contract has a completion date of November 8, 2023 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Ondansetron ODT 4 mg tablets. The award, valued at $7,649.00, was made by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense (DoD). The contract is a delivery order with a firm fixed price, and the ultimate completion date is December 5, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $3,338.97, is a Firm Fixed Price Delivery Order that runs through December 28, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,380.82 to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4560894640 - Ondansetron ODT 4 mg Tablet 30s, with a completion date of May 11, 2023. This is a firm-fixed price contract, and no set-aside designation was used. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award, valued at $3,379.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award is for the delivery of 4,560,993,787 units of Ondansetron ODT 4 mg Tablet 30s, a pharmaceutical product. The contract has an ultimate completion date of May 22, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB24FL10UDelivery Order
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Ondansetron ODT 4 mg tablets. The contract, valued at $1,927.30, is a firm-fixed price delivery order that runs through December 20, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition. Cencora, Inc., the parent company of Amerisourcebergen Drug Corp, also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 12/19/23 |